10x Faster Virus Neutralization Testing With Launch of Integral Molecular's Ready Reporter Virus™ Kit

Automation-compatible, safe assay delivers same-day results to accelerate vaccine and therapeutic antibody development

PHILADELPHIA, Oct. 14, 2025 /PRNewswire/ -- Integral Molecular, a leader in developing innovative tools for antiviral research, announces the launch of its Ready Reporter Virus™ (RRV) neutralization assay kit. This automation-compatible, safe assay assesses the effectiveness of vaccines and therapeutic antibodies and is set to transform how virus neutralization testing is performed. While conventional assays can take up to a week, the RRV kit delivers results in under 4 hours—10 times faster than current standards.

Learn more about RRVs , designed for high-throughput, automatable virus neutralization testing

Conventional neutralization assays are labor intensive, requiring live pathogenic virus, specialized biosafety facilities, cultivation of cells under sterile conditions, and often manual counting of results. These barriers make testing impossible for most laboratories worldwide. In contrast, RRVs do not replicate or cause disease and do not require cell culture, making this assay accessible to all scientists. RRV kits come with thaw-and-mix reagents and use simple workflows ideal for automation, a key consideration for scientists who need to screen hundreds or even thousands of samples.

Integral Molecular is the industry leader in providing viral particles to the vaccine industry, including its catalog of 100+ pseudotyped Reporter Virus Particles (RVPs) and Influenza TiterSafe™ Particles, a non-infectious alternative to the hemagglutination assay. RRVs expand this portfolio, giving scientists a powerful new way to perform rapid, safe virus neutralization experiments.

How RRV technology works

RRVs are non-pathogenic, non-replicative virus-based particles that display authentic native viral proteins on their surface. Like live viruses, RRVs enter human cells through natural receptor interactions, providing biologically relevant neutralization data for therapeutic candidates. The RRV kit supplies live target cells preloaded with a dye that provides a quantitative readout immediately upon virus entry, so an end user just needs to thaw and mix the supplied reagents to assess virus infection.

Applications of the RRV kit include:

• Serum testing from humans or animals for vaccine-induced neutralization
• Neutralization testing and lot-release for therapeutic antibodies
• Public health applications including disease surveillance

"Integral Molecular has long been committed to delivering safe, reliable tools that expand the ability of labs to conduct antiviral research critical for vaccine development," said Benjamin Doranz, PhD, CEO of Integral Molecular. "With RRVs, we are making neutralization testing not just faster, but also simpler, cost-effective, and more accessible for scientists who need robust, automatable assays without the burden of cell culture."

RRV kits are currently available for viruses including influenza, SARS-CoV-2, and VSV. Kits are manufactured under ISO 9001-certified quality processes and can be customized for additional viruses or variants of interest. RRVs will be launched in a presentation by Christina Go, PhD, at the World Vaccine Congress this week in Amsterdam.

About Integral Molecular

Integral Molecular (virology.integralmolecular.com) is the industry leader in creating transformative technologies that advance the discovery of therapeutics against difficult protein targets. With 20+ years of experience focused on viruses, antibodies, and membrane proteins, Integral Molecular's technologies have been integrated into the drug discovery pipelines of over 600 biotech and pharmaceutical companies to help discover new therapies for viral threats such as SARS-CoV-2, Ebola, Zika, and dengue viruses, as well as chronic diseases such as cancer, diabetes, and autoimmune disorders.

Follow Integral Molecular on LinkedIn

Press Contact
Integral Molecular
Soma Banik, PhD, Director of Public Relations
215-966-6061

SOURCE Integral Molecular